Jinarc (Tolvaptan)

tolvaptan 30 mg tablet [28] (&) tolvaptan 90 mg tablet [28], 56 · ORAL · PBS code 11596H

STREAMLINED

What it costs

AU$498.75 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2019-01-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Autosomal dominant polycystic kidney disease (ADPKD)

Continuing treatment

Must be treated by a nephrologist or in consultation with a nephrologist; AND

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have end-stage renal disease defined as an estimated glomerular filtration rate (eGFR) of less than 15 mL/min/1.73m2; AND

Patient must not have had a kidney transplant.

Sponsor: Otsuka Australia Pharmaceutical Pty. Ltd ABN 20 601 768 754

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.